Eli Lilly Expands Beyond Obesity Drugs With Engage Biologics Acquisition – Its 7th Acquisition This Year 

• Engage Biologics is developing the Tethosome platform, a non-viral DNA delivery system.
• Engage said its platform addresses major challenges such as immune sensing and efficient cellular delivery.
• Eli Lilly is set to present updates on its Retatrutide (diabetes drug) trial at the American Diabetes Association Scientific Sessions in June.

Shares of Eli Lilly and Company (LLY) remained in focus after the pharmaceutical giant marked its seventh acquisition of the year, deepening its push beyond blockbuster weight-loss drugs with the $202 million purchase of Engage Biologics, a genetic medicines developer.

LLY shares were up around 1% to their highest levels since March 2, 2026.

Engage Biologics Acquisition Opens Up DNA-Based Therapies Market For LLY

The acquisition underscores Lilly’s growing ambitions in next-generation DNA-based therapies. Engage Biologics, a California-based biotech firm, is developing the Tethosome platform, a non-viral DNA delivery system designed to improve the potency, tolerability, and re-dosability of genetic therapies.

The technology combines engineered DNA payloads, lipid nanoparticle delivery, and proprietary mRNA-based components. Engage said its platform addresses major challenges that have limited the use of non-viral DNA therapies, including immune sensing and efficient cellular delivery.

LLY Acquisitions Boost Oncology Pipeline

The company acquired Ventyx Biosciences for about $1.2 billion in January, and later struck deals for Ajax Therapeutics, Orna Therapeutics, and CrossBridge Bio to strengthen its presence in cancer, autoimmune disease, and CAR-T therapies.

In March, Eli Lilly and Company unveiled a $6.3 billion deal for Centessa Pharmaceuticals to strengthen its sleep disorder pipeline, followed a month later by the acquisition of Kelonia Therapeutics, a deal valued at up to $7 billion.

Retail Sentiment Remains Bearish

Retail sentiment for LLY on Stocktwits has been trending in the ‘bearish’ territory for at least a month.

One user said the stock is gearing up for a rally ahead of Retatrutide trial results next month.

In March, LLY reported positive Phase 3 results for the experimental diabetes drug in adults with type 2 diabetes. The treatment significantly lowered blood sugar levels and helped patients lose an average of 36.6 pounds over 40 weeks, compared with placebo. 

A detailed readout will take place next month at the American Diabetes Association Scientific Sessions.

The stock is down around 5% so far this year.

Read also: JUNS Stock Sees Best Single-Day Gains In Almost A Year On $100M MDMA Drug Licensing Deal  – Retail Expects Shares To Hit $1

For updates and corrections, email newsroom[at]stocktwits[dot]com.